Preclinical Oligonucleotide Drug Development: Insight from DMPK

Oligonucleotides comprise a rapidly growing class of therapeutics. However, due to their unique structure and characteristics, oligonucleotides have more technical challenges and unknown consequences for drug developers compared to more conventional drugs. In the preclinical stage, understanding absorption, distribution, metabolism, and excretion can pose unique challenges. Developing a customized approach to these DMPK studies specific to the characteristics of the oligonucleotide can provide key insights for further development in lead candidates for drug developers.

Watch the Webinar

Learning Objectives:

  • Understanding the unique DMPK considerations of oligonucleotides: absorption, distribution, metabolism, and excretion (ADME)
  • Understand the outcomes of these studies and how they can help support candidate selection in early phase development
  • Strategies for conducting insightful early stage DMPK assays for oligonucleotide development

WuXi AppTec DMPK Services

WuXi AppTec is a global leader in preclinical drug development testing and world-class expert in DMPK & ADME. We are a full-service, end-to-end testing partner, have screened tens of thousands of oligonucleotide molecules, and supported several through the IND application process.

Asset 1


DPMK Scientists



Global Clients

Asset 1-1


In Vitro Studies Per Year